Immix Biopharma Stock Analysis

Immix Stock Analysis Notes

About 40.0% of the company shares are held by company insiders. The company recorded a loss per share of 0.69. Immix Biopharma had not issued any dividends in recent years. Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company was incorporated in 2012 and is headquartered in Los Angeles, California. Immix Biopharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 2 people. To learn more about Immix Biopharma call the company at 310 651 8041 or check out https://www.immixbio.com.

Immix Biopharma Investment Alerts

Immix Biopharma Upcoming and Recent Events

Immix Largest EPS Surprises

View All Earnings Estimates

Immix Biopharma Environmental, Social, and Governance (ESG) Scores

Immix Stock Institutional Investors

Note, although Immix Biopharma's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Immix Market Capitalization

The company currently falls under 'Micro-Cap' category with a current market capitalization of 82.8 M.

Immix Profitablity

Management Efficiency

Immix Biopharma has return on total asset (ROA) of (0.5017) % which means that it has lost $0.5017 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.1234) %, meaning that it created substantial loss on money invested by shareholders. Immix Biopharma's management efficiency ratios could be used to measure how well Immix Biopharma manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.99 in 2025. Return On Capital Employed is likely to rise to -1.51 in 2025. At this time, Immix Biopharma's Net Tangible Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 2.9 M in 2025, whereas Total Assets are likely to drop slightly above 14.2 M in 2025.

Technical Drivers

As of the 19th of July, Immix Biopharma retains the Downside Deviation of 6.27, risk adjusted performance of 0.1818, and Market Risk Adjusted Performance of 0.8388. Immix Biopharma technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.

Immix Biopharma Price Movement Analysis

Immix Biopharma Insider Trading Activities

Immix Biopharma Outstanding Bonds

Immix Biopharma Predictive Daily Indicators

Immix Biopharma Forecast Models

Immix Biopharma's time-series forecasting models are one of many Immix Biopharma's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Immix Biopharma's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Immix Biopharma prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Immix shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Immix Biopharma. By using and applying Immix Stock analysis, traders can create a robust methodology for identifying Immix entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Immix analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Immix analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Immix Biopharma stock analysis indicators help investors evaluate how Immix Biopharma stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Immix Biopharma shares will generate the highest return on investment. By understating and applying Immix Biopharma stock analysis, traders can identify Immix Biopharma position entry and exit signals to maximize returns.

When running Immix Biopharma's price analysis, check to measure Immix Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immix Biopharma is operating at the current time. Most of Immix Biopharma's value examination focuses on studying past and present price action to predict the probability of Immix Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immix Biopharma's price. Additionally, you may evaluate how the addition of Immix Biopharma to your portfolios can decrease your overall portfolio volatility.